(6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline

Published date: 2024-05-09 14:01:29

Name	1H-Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline, 2,3,6b,7,8,9,10,10a-octahydro-3-methyl-, (6bR,10aS)	CAS#	313368-85-3
Price	￥Inquiry/1kg	Purity	99.0%
Stocking Period	Inquiry	Stock	Inquiry

Detail Product Information Chemical & Physical Properties: CAS Number: 313368-85-3 Name: 1H-Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline, 2,3,6b,7,8,9,10,10a-octahydro-3-methyl-, (6bR,10aS) Molecular Formula: C14H19N3 Molecular Weight: 229.32100 Density: 1.23±0.1g/cm3 Boiling Point: 374.5±42.0°C Melting Point: N/A Flash Point: N/A

Sichuan Taienkang Pharmaceutical Co., Ltd.

Chemsrc Level: Unverified
Tel: 0826-5999982
Address: No. 22, Jiankang Road, Economic Development Zone, Yuechi County, Guang'an City, Sichuan Province, China
Area: China
Contact: May Yang
Contact Phone #: 15102825326
Email: sales@taienkangpharma.com
Website: http://www.taienkangpharma.com/
Annual Trade Volume:
Foreign Trade % of Sales:
Major partners:

Sichuan Taienkang Pharmaceutical Co., Ltd. is a holding subsidiary of Guangdong Taienkang Pharmaceutical Co., Ltd. (stock code: 301263). It is a pharmaceutical company that integrates the research and development, production, and sales of generic APIs (active pharmaceutical ingredients) and advanced intermediates. The company was established in 2020, with a factory located in Yuechi County, Sichuan Province, China. The site covering a total area of 66,600 square meters. The production workshops are strictly in compliance with GMP standards and the production capacity is expected to reach 300 MT/year. The product portfolio covers a wide range of therapeutic areas and is designed and developed with technical barriers to bring value-added products.

The company’s management and R&D team are composed of senior experts with extensive experience in pharmaceutical products development, GMP management, as well as drug regulatory affairs. With our comprehensive understanding of drug development risk and GMP standard, the company's management and R&D team have been developed a series of trustworthy products preparation processes. The company has conducted a wide range of project cooperation with first tier pharmaceutical companies and research institutions in China. We also actively promoted business cooperation with world leading pharmaceutical companies, striving to expand into international markets.

2024-07-15	1H-Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline, 2,3,6b,7,8,9,10,10a-octahydro-3-methyl-, (6bR,10aS) Price: Inquiry
2021-07-26	1H-Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline, 2,3,6b,7,8,9,10,10a-octahydro-3-methyl-, (6bR,10aS)- Price: $Inquiry
2025-09-17	1H-Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline, 2,3,6b,7,8,9,10,10a-octahydro-3-methyl-, (6bR,10aS) Price: ￥Inquiry
2024-01-12	(6bR,10aS)-3-Methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline Price: ￥Inquiry